Research Topics
| Robert ApplegateSummaryAffiliation: Wake Forest University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularizationRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
J Am Coll Cardiol 40:78-83. 2002..The study assessed clinical outcomes of closure device use following percutaneous coronary revascularization using current standards of anticoagulation and antiplatelet therapy...- PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patientsRobert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
J Invasive Cardiol 18:604-13. 2006..Whether abciximab can be used safely or effectively during PCI for high-risk patients after upstream treatment with eptifibatide in patients with acute coronary syndromes (ACS) is not known... - Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction: from evidence to practiceN D Noureddine
Wake Forest School of Medicine, Section of Cardiology, Winston Salem, NC, USA
Minerva Cardioangiol 60:1-9. 2012..We will consider the evidence that evaluates the relative safety and efficacy of DES compared to BMS in STEMI patients, as well as address practical issues faced in the routine clinical care of these patients... 
Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stentsRobert J Applegate
Wake Forest School of Medicine, Winston Salem, NC 27157 1045, USA
EuroIntervention 7:1030-42. 2012..To evaluate whether the improved outcomes with newer generation drug-eluting stents (DES) utilising thin-strut stents are consistent among different patient and angiographic subgroups...- Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007Robert J Applegate
Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
JACC Cardiovasc Interv 1:317-26. 2008..This study sought to evaluate trends in vascular complications after diagnostic cardiac catheterization (CATH) and percutaneous coronary intervention (PCI) from the femoral artery from 1998 to 2007... - Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention using thrombin hemostatic patch-facilitated manual compressionRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
J Invasive Cardiol 19:164-70. 2007..To evaluate the adjusted risk of vascular complications after thrombin hemostasis patch-facilitated manual compression (THP-MC) for femoral artery access site management... - Vascular complications in women after catheterization and percutaneous coronary intervention 1998-2005Robert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
J Invasive Cardiol 19:369-74. 2007..Whether awareness of this gender risk or implementation of strategies to reduce the overall incidence of vascular complications has had an effect on the incidence of vascular complications in women is unknown... - Culprit vessel PCI versus traditional cath and PCI for STEMIRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC, 27157 1045, USA
J Invasive Cardiol 20:224-8. 2008.... - "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stentsRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
J Am Coll Cardiol 51:607-14. 2008..The aim was to compare 2-year outcomes with the routine use of drug-eluting stents (DES) (>75% "off-label") with a comparable group treated with bare-metal stents (BMS)... - Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysisRobert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, North Carolina 27157 1045, USA
Catheter Cardiovasc Interv 72:7-12. 2008..To compare late outcomes with the routine use of drug-eluting stents (DES) compared with bare-metal stents (BMS) during percutaneous intervention (PCI) of saphenous vein grafts (SVGs)... - Incidence of coronary stent thrombosis based on academic research consortium definitionsRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
Am J Cardiol 102:683-8. 2008..Use of the ARC probable stent thrombosis paralleled rates of definite stent thrombosis alone, but partially masked the occurrence of late (>1 year) stent thrombosis in DESs compared with BMSs... - Treatment of ostial lesions using the Szabo technique: a case seriesRobert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC, USA
Catheter Cardiovasc Interv 72:823-8. 2008..We discuss relevant technical issues using this technique as well as potential advantages and disadvantages... - Prognostic implications of vascular complications following PCIRobert Applegate
Wake Forest School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, North Carolina, USA
Catheter Cardiovasc Interv 74:64-73. 2009..To evaluate the effect of vascular complications (VC) on the adjusted risk of nonfatal myocardial infarction (MI) or death following percutaneous coronary intervention (PCI) at 1 year in a large contemporary cohort... - 3-year comparison of drug-eluting versus bare-metal stentsRobert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, North Carolina 27157 1045, USA
JACC Cardiovasc Interv 2:231-9. 2009.... - Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomesRobert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
Circ Cardiovasc Interv 2:35-42. 2009..Drug-eluting stents (DES) may reduce this effect in select patients; however, whether this benefit occurs in high-risk lesions and patients in routine practice is not clear... - Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trialRobert Applegate
Wake Forrest University School of Medicine, Winston Salem, NC, USA
Catheter Cardiovasc Interv 76:644-51. 2010..To evaluate whether an everolimus-eluting stent (EES) with thinner stent struts and polymer results in less periprocedural myonecrosis and adverse outcomes... - Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trialRobert J Applegate
Wake Forest University Health Sciences, Winston Salem, NC, USA
EuroIntervention 6:437-46. 2010..To examine the two year clinical outcomes in dual-vessel disease from the SPIRIT III trial comparing the XIENCE V(r) everolimus-eluting stent (EES) to the TAXUS Express2(tm) paclitaxel-eluting stent (PES)... - Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)Robert J Applegate
Wake Forest University Health Sciences, Winston Salem, NC, USA
Am J Cardiol 107:833-40. 2011..From 1 year to 3 years hazard curves continued to diverge in favor of EES, consistent with an improving long-term safety and efficacy profile of EES compared to PES, with no evidence of late catchup... - Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and deathRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
Am J Cardiol 99:333-8. 2007.... - Restick following initial Angioseal useRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Catheter Cardiovasc Interv 58:181-4. 2003..There were no major bleeding, vascular repair, vessel occlusion, or embolizations. Three large hematomas (1.7%) were noted. These data suggest that restick can be performed safely after initial Angioseal deployment... - The Angio-Seal Evolution registry: outcomes of a novel automated Angio-Seal vascular closure deviceRobert J Applegate
Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
J Invasive Cardiol 22:420-6. 2010.... - Restenosis of a sirolimus drug-eluting stent: aorto-ostial involvement of the proximal right coronary arteryRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Catheter Cardiovasc Interv 67:391-5. 2006..We discuss issues relevant to management of the restenotic drug-eluting stent in the aorto-ostial location... - Vascular complications with newer generations of angioseal vascular closure devicesRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
J Interv Cardiol 19:67-74. 2006..To evaluate the safety and efficacy of newer generations of a single vascular closure device (VCD), Angioseal, compared to contemporaneous manual compression... - Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003Robert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1045, USA
Catheter Cardiovasc Interv 67:556-62. 2006..To evaluate the adjusted risk of vascular complications after manual compression and vascular closure devices for femoral artery access site management in a large contemporary cohort, using propensity score analysis... - Bivalirudin and DES: a PCI strategy that paysRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
J Invasive Cardiol 19:69-70. 2007 - Transitioning to the radial artery as the preferred access site for cardiac catheterization: an academic medical center experienceSamuel Turner
Section of Cardiology, Wake Forest School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina, USA
Catheter Cardiovasc Interv 80:247-57. 2012.... - Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomesKevin R Hayes
Wake Forest University School of Medicine, Section of Cardiology, Winston Salem, NC 27157 1045, USA
J Invasive Cardiol 22:266-70. 2010..We sought to examine the clinical presentations and subsequent clinical outcomes of patients undergoing target lesion revascularization (TLR) after either bare-metal stent (BMS) or drug-eluting stent (DES) placement... - Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventionsEfthymios N Deliargyris
Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA
J Invasive Cardiol 16:611-6. 2004..Our data suggest that significant efficacy differences may exist between these 2 agents and that a randomized comparison is warranted... - Automated contrast injection in contemporary practice during cardiac catheterization and PCI: effects on contrast-induced nephropathyJason Call
Winchester Cardiology and Internal Medicine, Inc, Winston-Salem, North Carolina, USA
J Invasive Cardiol 18:469-74. 2006.... - Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein graftsBharathi Upadhya
Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Am J Cardiol 96:515-8. 2005..3% vs 72.4%; odds ratio 3.7; 95% confidence interval 2.2 to 6.3). Thus, an elevated preprocedural WBC count is associated with increased risk of MACEs in patients undergoing PCI for saphenous vein graft lesions... - Safety of abciximab administration during PCI of patients with previous strokeEfthymios N Deliargyris
Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1045, USA
J Thromb Thrombolysis 19:147-53. 2005..CONCLUSIONS: Abciximab, in addition to aspirin, heparin and ADP-inhibitors does not increase the risk of stroke in patients with prior stroke undergoing PCI... - Late outcomes after intervention of vein grafts in diabetics with abciximab useRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
Int J Cardiol 111:136-41. 2006..We sought to evaluate late clinical outcomes following elective percutaneous coronary interventions for saphenous vein graft with planned abciximab use in diabetics... - Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary interventionBharathi Upadhya
Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1045, USA
J Invasive Cardiol 17:243-7. 2005..271, respectively. CONCLUSION: Patients with prior stroke constitute a high-risk PCI cohort with higher rates of in-hospital adverse events. A prior stroke history should be considered in evaluating potential candidates for PCI... - Treatment of complex LAD-diagonal bifurcation disease using paclitaxel drug-eluting stentsRobert J Applegate
Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA
J Invasive Cardiol 17:390-2. 2005 - Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarctionNathan D Lambert
Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
Am Heart J 157:688-94. 2009..Whether moderate CKD and proteinuria increase the risk of ST after MI is not known. This study evaluated the risk of ST associated with moderate CKD and dipstick proteinuria... - Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary interventionScott A McKee
Wake Forest University School of Medicine, Winston Salem, NC, USA
Am Heart J 154:159-64. 2007..We postulated that cocaine use would be associated with increased risk for stent thrombosis... - Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stentingTerry R Ketch
Cardiology Section, Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
Am Heart J 156:234-40. 2008..We determined whether PTDF predicts events in patients with MI and compared this assay with brain natriuretic peptide (BNP) and C-reactive protein (CRP)... - ABO blood types: influence on infarct size, procedural characteristics and prognosisTerry R Ketch
Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045, USA
Thromb Res 123:200-5. 2008..However, the effect of blood group status on size of MI, procedural findings and outcomes after PCI for MI have not been reported... - Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarctionJames G Jollis
Department of Cardiology, Duke University, Durham, North Carolina, USA
JAMA 298:2371-80. 2007..Despite 2 decades of evidence demonstrating benefits from prompt coronary reperfusion, registries continue to show that many patients with ST-segment elevation myocardial infarction (STEMI) are treated too slowly or not at all... - Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrelJ Emilio Exaire
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Catheter Cardiovasc Interv 64:369-72. 2005..While minor and major TIMI bleeding remained very low in both groups, CD was associated with a twofold increase in risk of any-bleeding event when compared to MC, especially when using GP IIb/IIIa inhibitors... - Vascular closure devices: the second decadeHarold L Dauerman
Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
J Am Coll Cardiol 50:1617-26. 2007..Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices... - Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trialDavid E Kandzari
Duke Clinical Research Institute, Durham, North Carolina 27705, USA
J Am Coll Cardiol 48:2440-7. 2006..This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES)... - A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) StudyDavid J Moliterno
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Am Coll Cardiol 42:1132-9. 2003..Morrisville, North Carolina), a new point-of-care test... - Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levelsJacqueline Saw
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
Thromb Res 112:301-6. 2003..This novel test can be used for rapid bedside measurements of enoxaparin anticoagulant activity...